A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) (NCT06514794)
A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in Patients With Relapsed/Refractory Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma (T-RRex)
🩺 Plain-English Summary (8th-Grade Level)
The T-RRex study evaluates the efficacy of WU-CART-007 for patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL) and to WU-CART-007 as a therapy to induce complete Minimum Residual Disease (MRD) negative response
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 1 Year
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (17 Sites)
- City of Hope — Duarte, California
- Children's Hospital Los Angeles — Los Angeles, California
- Colorado Blood Cancer Institute — Denver, Colorado
- Children's National Hospital — Washington D.C., District of Columbia
- H. Lee Moffitt Cancer Center and Research Institute Hospital — Tampa, Florida
- Children's Hospital of Atlanta — Atlanta, Georgia
- Washington University Saint Louis — St Louis, Missouri
- Oncology Hematology Care — Cincinnati, Ohio
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania
- TriStar Bone Marrow Transplant / Sarah Cannon Transplant & Cellular Therapy — Nashville, Tennessee
- MD Anderson Cancer Center — Houston, Texas
- Sarah Cannon Transplant and Cellular Therapy Methodist Hospital — San Antonio, Texas
- Sarah Cannon, Virginia Oncology Associates — Norfolk, Virginia
- Seattle Children's Hospital — Seattle, Washington
- Peter Mac Callum Cancer Institute — Melbourne, Victoria
- Royal Children's Melbourne — Melbourne, Victoria
📞 Contact the Study Coordinator
Phone: (314) 501-1968
Email: clinicaltrials@wugen.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in T-cell Acute Lymphoblastic Leukemia
- Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL) — San Diego, California
- Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA With High Risk T-Cell ALL & Lymphoma — Phoeniz, Arizona
- A Phase 2 Study to Evaluate Efficacy of Calaspargase Pegol-mknl and Decitabine Combined With Venetoclax in Pediatric, Adolescent, and Young Adult Patients With Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia (T-ALL) and T- Cell Lymphoblastic Lymphoma (T-LLy) — Houston, Texas
- Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma — Houston, Texas
- Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALL — Chicago, Illinois
Explore by condition: All T-cell Acute Lymphoblastic Leukemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.